Loading...
•
Sep 30, 2023
Integra LifeSciences Q3 2023 Earnings Report
Integra LifeSciences' Q3 2023 financial performance was impacted by Boston returns, but demonstrated strong organic growth in Codman Specialty Surgical and Tissue Technologies businesses, excluding Boston.
Key Takeaways
Integra LifeSciences reported Q3 2023 revenues of $382.4 million, a decrease of 0.7% on a reported basis and 0.4% on an organic basis compared to the prior year. GAAP earnings per diluted share were $0.24, while adjusted earnings per diluted share were $0.76. The company is updating its full-year 2023 revenue and adjusted earnings per share guidance to a range of $1.541 billion to $1.547 billion and $3.10 to $3.14 respectively.
Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year.
Third quarter GAAP earnings per diluted share of $0.24, compared to $0.60 in the prior year; adjusted earnings per diluted share of $0.76, compared to $0.86 in the prior year.
Successfully completed all interim external inspections in preparation for the Boston manufacturing facility restart and remain on track to committed timelines.
Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of $1.541 billion to $1.547 billion and $3.10 to $3.14 respectively.
Forward Guidance
The Company is updating its revenue and adjusted EPS expectations to $1.541 to $1.547 billion and $3.10 to $3.14, respectively.
Positive Outlook
- Expect to restart manufacturing in Boston by end of Q4’23
- Resume commercial distribution in mid-to late Q2’24
- Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of $1.541 billion to $1.547 billion and $3.10 to $3.14 respectively
- For the fourth quarter 2023, the Company expects reported revenues in the range of $397 million to $403 million
- Adjusted earnings per diluted share are expected to be in the range of $0.89 to $0.93
Challenges Ahead
- The revenue range represents reported growth of -1.1% to -0.7%, with organic growth of 0.1% to 0.5%, reflecting the impact of higher-than-expected Boston recall returns
- Organic growth excludes sales from the divestiture of the Company’s traditional wound care (TWC) business as of September 1, 2022
- Organic growth excludes sales from the acquisition of Surgical Innovation Associates, Inc. (SIA) through December 1, 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...